Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT)
C.Y. VOSSEN(Leiden University Medical Center), Frits R. Rosendaal(Leiden University Medical Center), Ingrid Pabinger(Medical University of Vienna), Isobel D. Walker(British Society for Haematology), Juan Carlos Souto, Michael Makris(University of Sheffield), F.J.M. van der Meer(Leiden University Medical Center), J. Fontcuberta(Institut de Ciència de Materials de Barcelona), I. Scharrer(Goethe University Frankfurt), J. Conard(Hôtel-Dieu de Paris), Peter J. Svensson(Skåne University Hospital), F E Preston(Royal Hallamshire Hospital), Gualtiero Palareti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola)
Cited by 202
Related Papers
von Willebrand Factor–Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolytic–Uremic Syndrome
|New England Journal of Medicine|1998|1.7k
Oral Anticoagulant Therapy
|CHEST Journal|2012|1.5k
Incidence and mortality of venous thrombosis: a population‐based study
|Journal of Thrombosis and Haemostasis|2007|1.4k
Evidence-Based Management of Anticoagulant Therapy
|CHEST Journal|2012|1.3k